AVENUE THERAPEUTICS, INC. Quarterly Operating Income (Loss) in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Avenue Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2016 to Q3 2024.
  • Avenue Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$3.16M, a 52.6% decline year-over-year.
  • Avenue Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$11.8M, a 27.7% increase year-over-year.
  • Avenue Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$14.5M, a 80.8% decline from 2022.
  • Avenue Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$8.04M, a 115% decline from 2021.
  • Avenue Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$3.74M, a 28.3% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$11.8M -$3.16M -$1.09M -52.6% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$10.7M -$2.82M +$1.1M +28% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-09
Q1 2024 -$11.8M -$3.71M +$2.72M +42.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$14.5M -$2.12M +$1.79M +45.8% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-18
Q3 2023 -$16.3M -$2.07M -$1.41M -212% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$14.9M -$3.92M -$3.32M -548% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 -$11.6M -$6.43M -$3.57M -125% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$8.04M -$3.91M -$3M -328% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-18
Q3 2022 -$5.05M -$663K +$209K +24% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$5.25M -$605K +$346K +36.4% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$5.6M -$2.86M -$1.86M -186% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 -$3.74M -$914K +$85K +8.51% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-31
Q3 2021 -$3.82M -$872K +$165K +15.9% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-10
Q2 2021 -$3.99M -$951K +$952K +50% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$4.94M -$1M +$273K +21.4% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$5.21M -$999K +$4.48M +81.8% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-25
Q3 2020 -$9.69M -$1.04M +$1.29M +55.4% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 -$11M -$1.9M +$5.21M +73.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 -$16.2M -$1.27M +$10.1M +88.8% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-17
Q4 2019 -$26.3M -$5.47M -$1.37M -33.4% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$24.9M -$2.32M +$285K +10.9% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-04
Q2 2019 -$25.2M -$7.11M -$2.43M -51.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$22.8M -$11.4M -$935K -8.97% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$21.8M -$4.1M +$2.22M +35.1% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 -$24M -$2.61M +$240K +8.43% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$24.3M -$4.68M -$2.94M -168% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$21.3M -$10.4M -$9.92M -1968% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q4 2017 -$11.4M -$6.33M -$5.81M -1126% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-12
Q3 2017 -$5.61M -$2.85M -$2.47M -644% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
Q2 2017 -$3.15M -$1.74M -$1.11M -173% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-14
Q1 2017 -$2.04M -$504K +$336K +40% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-03
Q4 2016 -$2.38M -$516K Oct 1, 2016 Dec 31, 2016 10-K 2018-03-01
Q3 2016 -$383K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 -$638K Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-11
Q1 2016 -$840K Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.